QS Research · Michael Burry's Scion Capital analyst template · 2006
Tempus AI, Inc. (TEM)
As of 2026-11-20 · 12/15 boxes filled from SEC filings and market data
Report price $54.04 (close 2026-11-20)
Conclusion: WATCH
Conviction low · base case -48% · downside -62% · upside +19%
Despite a 39.3% drawdown from the 52-week high, the market is not missing the growth: it pays 6.26x TTM sales for a business with -$249.3M EBITDA, -$136.8M free cash flow and a -132.0% ROIC against a 19.2% WACC. The base case puts the stock at $28.16, -47.9%, on EV/Sales at 3.13x, the peer median; the downside is $20.39, -62.3%, on the base case's multiple applied to earnings 30.0% lower; the upside is $64.39, +19.2%, on 20% more sales at today's 6.26x. Data licensing, the $590.5M cash balance and the about $65M FY2026 adjusted EBITDA guide are real, but they do not yet produce GAAP profit or positive free cash flow. The call is WATCH with low conviction: this is a growth compounder read on a deep-value checklist, where the reverse DCF needing +33.0% a year for ten years is the fairer test, and the peer anchor is weak because the comps grow at different rates.
Key numbers
- Share price: $54.04
- Market cap: $9.86B
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $1.51B
- FCF yield: -1.4%
- Price / book: 19.70x
- Earnings-quality flags (TTM): Investment gains/losses $120.7M (64% of net income)
- Revenue growth (latest fiscal year): +83.4%
- ROIC (TTM): -132.0%
- WACC: 19.2%
- Economic profit spread: -151.2 pts
The 15 boxes
- ✓ 1. Long-form business notes
Tempus (filed as Tempus Labs, Inc. until the December 2023 rename) sells next-generation sequencing and other diagnostic testing to providers and monetizes a de-identified copy of the resulting clinical and molecular data to life sciences customers. The latest 10-K folds the business into two product lines — Diagnostics (Oncology and Hereditary testing) and Data and applications (Insights, Next, Trials, Algos) — replacing the FY2024 three-line structure of Genomics, Data and AI Applications/Algos. Revenue grew in every year shown, from $320.7M in FY2022 to $1.27B in FY2025 and $1.51B TTM to Sep 30 2026, but operating income is still a loss (-$252.9M FY2025, -$278.9M TTM) and operating cash flow is negative (-$218.1M FY2025, -$108.4M TTM), with $590.5M of cash at Sep 30 2026. Between the oldest and newest annual report the ordering-site network widened from roughly 3,000 to more than 5,000 institutions, largely on the February 2025 Ambry Genetics acquisition that pushed the company beyond oncology.
- ✓ 2. Competitive advantage
No durable advantage is visible in the numbers: Tempus has grown revenue from $320.7M in FY2022 to $1.27B in FY2025 and $1.51B TTM to Sep 2026, yet operating income was negative in every period and operating cash flow was negative in every period including -$108.4M TTM, with an accumulated deficit of $2.4 billion at 2025-12-31. The competitive set is crowded and well funded — Foundation Medicine/Roche, Caris, Guardant, Natera, Neogenomics, plus Quest and LabCorp in labs, and Flatiron, IQVIA and ConcertAI in data — and the company itself warns many rivals have substantially greater resources. Its claimed moat (network effects, proprietary technology, data) is asserted rather than demonstrated: some data-supplier arrangements are non-exclusive, and only ~55% of clinical oncology NGS tests and 50% of hereditary tests performed since 2023-01-01 had been paid as of 2025-12-31.
- ✓ 3. 10-Q takeaways
Q3 2026 revenue was $411.5 million, up 23%, and nine-month revenue was $1,142.1 million, up 26%, led by Diagnostics and Data & Applications growth. Gross profit rose 27% to $266.7 million and Adjusted EBITDA was $25.6 million, while the $(14.9) million net loss included large unrealized securities gains and stock-based compensation. Cash and marketable securities were $854.4 million, and full-year 2026 guidance is $1.60 to $1.605 billion of revenue with about $65 million of Adjusted EBITDA. The 10-Q risk-factor update says no material changes except risks tied to the proposed Personalis acquisition.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ○ 11. Impression of the shareholder letter
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.